News GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 10:47:25 2024-04-24 am EDT			5-day change	1st Jan Change
1,639 ^GBX	-0.71%		+3.29%	+13.24%

04:39pm	GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	MT
04:27pm	CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	10:39am	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	10:27am	MT
GSK : Gets a Sell rating from JP Morgan	07:52am	ZD
GSK : Gets a Buy rating from Bernstein	07:38am	ZD
US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	07:15am	AQ
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	06:45am	CI
GSK: FDA priority review for endometrial cancer	04:51am	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	04:14am	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	03:12am	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	02:16am	RE
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
GSK : Director/Pdmr Shareholding - Form 6-K	Apr. 19	PU
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	Apr. 17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	Apr. 17	AQ
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	Apr. 17	PU
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST